# Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)

> **NCT04839146** · PHASE1 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 45 (actual)

## Conditions studied

- Covid19
- Severe Acute Respiratory Syndrome
- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** ABNCoV2 Vaccine

## Key facts

- **NCT ID:** NCT04839146
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-11
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-02-25
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04839146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04839146, "Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04839146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*